Chemoimmunotherapy in Advanced, PD-1 Refractory Cutaneous Squamous Cell Carcinoma: Insights From Two Immunocompromised Patient Cases
Cutaneous squamous cell carcinoma (cSCC) is one of the most prevalent malignancies worldwide, and a subset of patients, particularly immunocompromised individuals, will face heightened risks of metastasis and mortality. This report examines two cases of immunocompromised patients treated with a comb...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | Case Reports in Oncological Medicine |
| Online Access: | http://dx.doi.org/10.1155/crom/4443916 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Cutaneous squamous cell carcinoma (cSCC) is one of the most prevalent malignancies worldwide, and a subset of patients, particularly immunocompromised individuals, will face heightened risks of metastasis and mortality. This report examines two cases of immunocompromised patients treated with a combination of platinum- and taxane-based chemotherapy together with PD-1 inhibition, having progressed after PD-1 monotherapy. The first patient, a 54-year-old man with HIV and recurrent metastatic cSCC, had rapid progression of disease while undergoing PD-1 inhibition with cemiplimab but later achieved tumor control when treated with pembrolizumab, carboplatin, and paclitaxel. The second patient, a 36-year-old man with cystic fibrosis and a history of lung transplantation, had no signs of response to cemiplimab but experienced a partial response when treated with cemiplimab, carboplatin, and paclitaxel. These cases suggest that combining chemotherapy with PD-1 inhibition may help overcome primary resistance to PD-1 therapy in advanced cSCC. |
|---|---|
| ISSN: | 2090-6714 |